MedTrace Logo

Multicenter Study of Fulminant Type 1 Diabetes in China

NCT05593081 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2022-10-25

No results posted yet for this study

Summary

This study took FT1D（fulminant type 1 diabetes） as the research object, collected the cases of FT1D patients, and described the clinical characteristics of this type of disease. The HLA susceptibility genes of FT1D were identified by PCR and other techniques, taking age-sex-matched healthy subjects as controls and HLA genes as the research entry point.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

GENETIC

HLA

Distinguish based on clinical features

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05593081 on ClinicalTrials.gov